Product Description
Mechanisms of Action: M2 Antagonist
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Avera
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Anesthesia Related
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2004-004728-11 | P2 |
Completed |
Anesthesia Related |
2005-12-13 |
|
MR/EUM202 | P2 |
Completed |
Anesthesia Related |
None |